Belite Bio (BLTE) Stock Forecast, Price Target & Predictions
BLTE Stock Forecast
Belite Bio stock forecast is as follows: an average price target of $60.00 (represents a -6.43% downside from BLTE’s last price of $64.12) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
BLTE Price Target
The average price target for Belite Bio (BLTE) is $60.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $60.00 to $60.00. This represents a potential -6.43% downside from BLTE's last price of $64.12.
BLTE Analyst Ratings
According to 1 Wall Street analysts, Belite Bio's rating consensus is 'Buy'. The analyst rating breakdown for BLTE stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Belite Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 13, 2024 | Yi Chen | H.C. Wainwright | $60.00 | $48.55 | 23.58% | -6.43% |
The latest Belite Bio stock forecast, released on Aug 13, 2024 by Yi Chen from H.C. Wainwright, set a price target of $60.00, which represents a 23.58% increase from the stock price at the time of the forecast ($48.55), and a -6.43% decrease from BLTE last price ($64.12).
Belite Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $60.00 |
| Last Closing Price | $64.12 | $64.12 | $64.12 |
| Upside/Downside | -100.00% | -100.00% | -6.43% |
In the current month, the average price target of Belite Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Belite Bio's last price of $64.12. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 12, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Belite Bio's last stock rating was published by H.C. Wainwright on Sep 12, 2024. The company gave BLTE a "Buy" rating, the same as its previous rate.
Belite Bio Financial Forecast
Belite Bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | May 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | $16.67M | - | - |
| High Forecast | - | - | - | - | $16.67M | - | - |
| Low Forecast | - | - | - | - | $16.67M | - | - |
| # Analysts | - | - | - | - | 1 | - | - |
| Surprise % | - | - | - | - | - | - | - |
Belite Bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. BLTE's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Belite Bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | May 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict BLTE's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Belite Bio's previous annual EBITDA (undefined) of $NaN.
Belite Bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | May 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-11.20M | $-9.51M | $-9.36M | $-9.36M | $-9.97M | $-8.84M | $-7.76M |
| High Forecast | $-11.20M | $-9.51M | $-9.36M | $-9.36M | $-9.09M | $-8.84M | $-7.76M |
| Low Forecast | $-11.20M | $-9.51M | $-9.36M | $-9.36M | $-10.56M | $-8.84M | $-7.76M |
| Surprise % | - | - | - | - | - | - | - |
Belite Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BLTE's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Belite Bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | May 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Belite Bio's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to BLTE last annual SG&A of $NaN (undefined).
Belite Bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | May 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.36 | $-0.31 | $-0.30 | $-0.30 | $-0.33 | $-0.29 | $-0.26 |
| High Forecast | $-0.36 | $-0.31 | $-0.30 | $-0.30 | $-0.30 | $-0.29 | $-0.26 |
| Low Forecast | $-0.36 | $-0.31 | $-0.30 | $-0.30 | $-0.34 | $-0.29 | $-0.26 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Belite Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BLTE previous annual EPS of $NaN (undefined).
Belite Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IMRX | Immuneering | $1.73 | $17.50 | 911.56% | Buy |
| VIGL | Vigil Neuroscience | $1.73 | $11.00 | 535.84% | Buy |
| MOLN | Molecular Partners | $5.25 | $29.00 | 452.38% | Buy |
| AVTE | Aerovate Therapeutics | $2.56 | $13.00 | 407.81% | Hold |
| ANEB | Anebulo Pharmaceuticals | $1.31 | $6.00 | 358.02% | Buy |
| PMVP | PMV Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| LRMR | Larimar Therapeutics | $4.32 | $17.00 | 293.52% | Buy |
| ANTX | AN2 Therapeutics | $1.34 | $5.00 | 273.13% | Buy |
| ACRV | Acrivon Therapeutics | $7.21 | $22.50 | 212.07% | Buy |
| ANAB | AnaptysBio | $15.99 | $49.83 | 211.63% | Buy |
| CELC | Celcuity | $12.55 | $39.00 | 210.76% | Buy |
| MLYS | Mineralys Therapeutics | $12.35 | $30.00 | 142.91% | Buy |
| ADAG | Adagene | $2.10 | $5.00 | 138.10% | Buy |
| GLTO | Galecto | $5.24 | $10.00 | 90.84% | Buy |
| CNTA | Centessa Pharmaceuticals | $17.60 | $23.25 | 32.10% | Buy |
| TRDA | Entrada Therapeutics | $18.45 | $20.00 | 8.40% | Buy |
| BLTE | Belite Bio | $63.06 | $60.00 | -4.85% | Buy |
| IKNA | Ikena Oncology | $1.62 | $1.33 | -17.90% | Buy |
| AADI | Aadi Bioscience | $2.39 | $1.63 | -31.80% | Hold |
| ALGS | Aligos Therapeutics | $34.47 | $3.00 | -91.30% | Hold |